Equity Profile

RYTM

RHYTHM PHARMACEUTICA

Health CareBiotechnology$5.9B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Rhythm Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders related to obesity....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RYTM Q2-2026 Earnings Preview

Context

Company Snapshot

Rhythm Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders related to obesity. With a market cap of $6 billion, its work is crucial in addressing unmet medical needs in the health care sector, particularly as the demand for effective treatments for obesity-related conditions continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-1.49%

Avg Stock Reaction

+1.37%

Last Quarter Recap

In Q1 2026, Rhythm Pharmaceuticals reported an EPS of -$0.83, slightly beating expectations by 3.04%. The stock reacted positively, gaining 7.86% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Rhythm Pharmaceuticals are mixed, with investors closely watching for any signs of revenue growth and updates on clinical trials.

Bull Case

If the company can show significant progress in its clinical trials and better-than-expected revenue, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the earnings report reveals disappointing trial results or continued losses, it may lead to a negative sentiment and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on the clinical trials for the lead product candidate?

Investors will be keen to hear about any advancements or setbacks, as these updates can significantly impact future revenue potential.

How does the company plan to address ongoing losses in the upcoming quarters?

Understanding the management's strategy for profitability will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Rhythm's lead product to gain traction in the market, especially given the increasing focus on obesity treatments.

Supporting Evidence

The recent positive EPS surprise suggests that the company is making progress, contrary to bearish sentiments.

Options pricing indicates a significant expected move, which may reflect underlying bullish sentiment that isn't fully captured by analysts.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a reevaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Rhythm Pharmaceuticals can turn around its financial performance while advancing its product pipeline.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in losses by at least 15% compared to the previous quarter.

Bear Confirmed If

Reporting a wider loss than expected, indicating potential issues with product development or market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±24.03%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±11.6% while RYTM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.6%

Calls (900)P/C Ratio: 0.44Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 30 (47%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 30 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.6%, with a raw directional average of +2.5% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Rhythm beats expectations and raises guidance, history suggests the stock could jump by around 3.24%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience a muted reaction, reflecting uncertainty.

Miss

Should the company miss expectations, history indicates a potential decline of about 0.50%, leading to increased scrutiny of its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the clinical trials for the lead product candidate.
2Management's strategy for reducing losses and achieving profitability.
3Any new partnerships or collaborations that could enhance market reach.
4Insights into market demand for obesity treatments and how Rhythm plans to address it.
5Future guidance on revenue expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Rhythm Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders related to obesity....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth will provide insight into the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RYTM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-1.49%

Avg Stock Reaction

+1.37%

Last Quarter Recap

In Q1 2026, Rhythm Pharmaceuticals reported an EPS of -$0.83, slightly beating expectations by 3.04%. The stock reacted positively, gaining 7.86% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Rhythm Pharmaceuticals are mixed, with investors closely watching for any signs of revenue growth and updates on clinical trials.

Bull Case

If the company can show significant progress in its clinical trials and better-than-expected revenue, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the earnings report reveals disappointing trial results or continued losses, it may lead to a negative sentiment and a drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on the clinical trials for the lead product candidate?

Investors will be keen to hear about any advancements or setbacks, as these updates can significantly impact future revenue potential.

How does the company plan to address ongoing losses in the upcoming quarters?

Understanding the management's strategy for profitability will be crucial for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Rhythm's lead product to gain traction in the market, especially given the increasing focus on obesity treatments.

Supporting Evidence

The recent positive EPS surprise suggests that the company is making progress, contrary to bearish sentiments.

Options pricing indicates a significant expected move, which may reflect underlying bullish sentiment that isn't fully captured by analysts.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a reevaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Rhythm Pharmaceuticals can turn around its financial performance while advancing its product pipeline.

Bull Confirmed If

Demonstrating a clear path to profitability with a reduction in losses by at least 15% compared to the previous quarter.

Bear Confirmed If

Reporting a wider loss than expected, indicating potential issues with product development or market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±24.03%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±11.6% while RYTM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.6%

Calls (900)P/C Ratio: 0.44Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 30 (47%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Rhythm beats expectations and raises guidance, history suggests the stock could jump by around 3.24%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience a muted reaction, reflecting uncertainty.

Miss

Should the company miss expectations, history indicates a potential decline of about 0.50%, leading to increased scrutiny of its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the clinical trials for the lead product candidate.
2Management's strategy for reducing losses and achieving profitability.
3Any new partnerships or collaborations that could enhance market reach.
4Insights into market demand for obesity treatments and how Rhythm plans to address it.
5Future guidance on revenue expectations for the next quarter.